

REGISTERED COMPANY NUMBER: 08066385 (England & Wales)
REGISTERED CHARITY NUMBER: 1151744

**Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 May 2023
for
aPODD Foundation**

SATURDAY



ACW2NHMH

A7

03/02/2024

#80

COMPANIES HOUSE

aPODD Foundation
Contents of the Financial Statements
for the year ended 31 May 2023

	Page
Report of the Trustees	2
Independent Examiner's Report	5
Statement of Financial Activities	6
Balance Sheet	7
Notes to the Financial Statements	8

aPODD Foundation

Report of the Trustees
for the year ended 31 May 2023

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 May 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

OBJECTIVES AND ACTIVITIES

Public Benefit

Cancer is the major cause of death by diseases for children in Europe and North America.

The international paediatric oncology community has done a great job in improving outcomes for children with cancer but some limitations still persist and hamper progress. By and large sick children are treated with old, rather toxic drugs that were developed as far as 50 years ago. They are largely denied access to the most innovative therapies because these new treatments are normally developed for adult cancers, which are different from those occurring in children. There are no compelling financial incentives for the pharmaceutical industry to develop specific medicines for children.

aPODD's mission is to fill this gap and accelerate the introduction of better and safer treatment for children with cancer.

One approach currently pursued is drug re-purposing, which consists in studying drugs that are currently approved for the treatment of certain diseases and assess whether they could be used effectively to treat other diseases, such as childhood cancer for example. By funding research and development into drug repurposing at the preclinical level (i.e. laboratory tests on cells and animal models), aPODD aims at the identification of potential candidates for clinical testing. The generation of such candidates is very valuable for the clinical community, as paediatric oncologists may then be in a position to offer possible therapeutic options to patients that have ceased to respond to conventional therapy and face a poor prognosis.

Additionally, by combining these new, re-purposed treatments it is theoretically possible to reduce the doses of the conventional chemotherapeutic drugs, thus reducing the toxicity to patients.

aPODD Foundation

Report of the Trustees for the year ended 31 May 2023

ACHIEVEMENT AND PERFORMANCE

Charitable Activities

The charity is dedicated to activities that accelerate the identification and development of better therapies for children and adolescents with cancer.

Over the past year we have taken part to the activities organized by ACCELERATE Platform and attended the annual event. We continued to spread awareness about the need of more effective drug development efforts for children and adolescents with cancer.

aPODD continued to work on the Neuroblastoma project in collaboration with ENEA Foundation in Italy and the University of Lund in Sweden. The lab in Lund has generating very interesting data and is continuing to work on this project in order to collect additional data and present the findings at international conferences and in the form of a scientific publication. In parallel we are contacting third parties and discuss possible collaboration opportunities for follow up work.

The Medulloblastoma project remains on hold, for the time being.

aPODD had continued its dialogue with European and US-based childhood cancer charities in order to launch a new drug repurposing projects for various childhood cancers.

aPODD trustees participated and presented at international scientific conferences and the charity continued its advocacy-related activities to raise awareness of the need for better cancer therapies for children and adolescents.

FINANCIAL REVIEW

Reserves Policy

The charity still operates with a small budget. There are currently no paid staff members or volunteers. All the activities have been so far carried out either by the trustees on a voluntary, pro-bono, basis or by consultants on fixed terms contracts. We are committed to start projects only in the case we have sufficient funds to cover activities up to a defined milestones. The charity's board aims at ensuring that every year there will be sufficient funds to cover all the basic operating expenses that are deemed necessary to support the continuation of the charity's activities.

FUTURE PLANS

aPODD will continue providing support for the ongoing drug repurposing projects. The charity is currently evaluating possible international collaborations with like-minded organisations in Europe and North America. We have started a dialogue with LifeArc and Deep Science Venture in the UK in view of possible future partnerships.

We will continue our collaboration with the ENEA foundation in Italy for the Neuroblastoma project. Once the preclinical project is completed, we will work with the University of Lund and Healx to submit a publication of our result.

aPODD will continue its involvement within the ACCELERATE multi-stakeholder platform and the CAC2 network in the US.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing Document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

aPODD Foundation

Report of the Trustees
for the year ended 31 May 2023

STRUCTURE, GOVERNANCE AND MANAGEMENT

Induction and training of new trustees

New trustees are selected and trained according to the guidelines published by the Charities Commission. Any new trustee has been introduced to the board by an existing trustee. The candidates have been selected on the basis of their professional experience, track record and enthusiasm for the charity's mission. In particular we have been interested to recruit trustees that would bring in complementary skills, in order to have a competent board, fully equipped to steer the charity in the right direction and support its development.

All new trustees receive copies of the published guidelines and have been adequately briefed on the current activities, either informally with email, telephone exchange and face to face meetings or more formally during the charity's board meetings.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered company number
08066385 (England and Wales)

Registered Charity number
1151744

Registered office
Virginia Cottage
Bridgnorth Road
Stourton
DY7 5BQ

Trustees	
D J Binner	Director
T Christely	Director
A Drijver	Company Director
M Janicot	Director
M Mathias	Consultant
E Mengou	Regulatory Affairs Specialist
C Spadoni	Director
A Westwood	Accountant
B Wulff	Medical Doctor

Independent Examiner
Grant Harrod Lerman Davis LLP
Chartered Accountants
1st Floor
Heathaid House
Marlborough Hill
Harrow
Middlesex
HA1 1UD

Approved by order of the board of trustees on 31st January 2024 and signed on its behalf by:


C Spadoni - Trustee

aPODD Foundation

**Independent Examiner's Report to the Trustees of
aPODD Foundation**

As the charity's income has not exceeded the statutory threshold during the period, it is exempt from obtaining an Independent Examiner's Report.

aPODD Foundation

Statement of Financial Activities
for the year ended 31 May 2023

	Notes	Unrestricted fund £	Restricted funds £	2023 Total funds £	2022 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		22	-	22	29
Charitable activities		-	-	-	-
Investment income	2	-	-	-	-
Total		<u>22</u>	<u>-</u>	<u>22</u>	<u>29</u>
EXPENDITURE ON					
Raising funds		-	-	-	-
Charitable activities		-	-	-	-
Total		<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
NET INCOME/(EXPENDITURE)		22	-	22	29
RECONCILIATION OF FUNDS					
Total funds brought forward		24,516	9,460	33,976	33,947
TOTAL FUNDS CARRIED FORWARD		<u>24,538</u>	<u>9,460</u>	<u>33,998</u>	<u>33,976</u>

CONTINUING OPERATIONS

All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements.

aPODD Foundation

Balance Sheet
As at 31 May 2023

	Notes	Unrestricted fund £	Restricted funds £	2023 Total funds £	2022 Total funds £
CURRENT ASSETS					
Cash at bank		24,538	9,460	33,998	33,976
CREDITORS					
Amounts falling due within one year	5	-	-	-	-
NET CURRENT ASSETS		<u>24,538</u>	<u>9,460</u>	<u>33,998</u>	<u>33,976</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		24,538	9,460	33,998	33,976
NET ASSETS		<u>24,538</u>	<u>9,460</u>	<u>33,998</u>	<u>33,976</u>
FUNDS					
Unrestricted funds				24,538	24,516
Restricted funds				9,460	9,460
TOTAL FUNDS				<u>33,998</u>	<u>33,976</u>

The charity is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2023


The members have not required the charitable company to obtain an audit of its financial statements for the year end 31 May 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as is applicable to the charitable company.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies.

The financial statements were approved by the Board of Trustees on 31st January 2024 and were signed on its behalf by:



C Spadoni - Trustee

The notes form part of these financial statements.

aPODD Foundation

Notes to the Financial Statements
For the year ended 31 May 2023

1. **ACCOUNTING POLICIES**

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS102, have been prepared in accordance with the Charities SORP (FRS102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2015), Financial Reporting Standard 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probably that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. **INVESTMENT INCOME**

	2023 £	2022 £
Deposit account interest	-	-

3. **TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees remuneration or other benefits for the year ended 31 May 2023 nor for the year ended 31 May 2022.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 May 2023 nor for the year ended 31 May 2022.

4. **COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted fund £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	29	-	29
Charitable activities	-	-	-
Total	29	-	29

aPODD Foundation

Notes to the Financial Statements
For the year ended 31 May 2023

4. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted fund £	Restricted funds £	Total funds £
EXPENDITURE ON			
Raising funds	-	-	-
Charitable activities	-	-	-
Total	-	-	-
NET INCOME/(EXPENDITURE)	29	-	29
RECONCILIATION OF FUNDS			
Total funds brought forward	24,487	9,460	33,947
TOTAL FUNDS CARRIED FORWARD	<u>24,516</u>	<u>9,460</u>	<u>33,976</u>

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Accruals and deferred income	-	-

6. MOVEMENT IN FUNDS

	At 1.6.22 £	Net movement in funds £	At 31.5.23 £
Unrestricted funds			
General fund	24,516	22	24,538
Restricted funds			
ENEA	-	-	-
Stripe	9,460	-	9,460
	<u>9,460</u>	<u>-</u>	<u>9,460</u>
TOTAL FUNDS	<u>33,976</u>	<u>22</u>	<u>33,998</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	22	-	22
Restricted funds			
ENEA	-	-	-
Stripe	-	-	-
	<u>-</u>	<u>-</u>	<u>-</u>
TOTAL FUNDS	<u>22</u>	<u>-</u>	<u>22</u>

aPODD Foundation

Notes to the Financial Statements
For the year ended 31 May 2023

6. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds	At 1.6.21 £	Net movement in funds £	At 31.5.22 £
Unrestricted funds			
General fund	24,487	29	24,516
Restricted funds			
ENEA	-	-	-
Stripe	9,460	-	9,460
	<u>9,460</u>	<u>-</u>	<u>9,460</u>
TOTAL FUNDS	<u>33,947</u>	<u>29</u>	<u>33,976</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	29	-	29
Restricted funds			
ENEA	-	-	-
Stripe	-	-	-
	<u>-</u>	<u>-</u>	<u>-</u>
TOTAL FUNDS	<u>29</u>	<u>-</u>	<u>29</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.6.21 £	Net movement in funds £	At 31.5.23 £
Unrestricted funds			
General fund	24,487	51	24,538
Restricted funds			
ENEA	-	-	-
Stripe	9,460	-	9,460
	<u>9,460</u>	<u>-</u>	<u>9,460</u>
TOTAL FUNDS	<u>33,947</u>	<u>51</u>	<u>33,998</u>

aPODD Foundation

Notes to the Financial Statements
For the year ended 31 May 2023

6. **MOVEMENT IN FUNDS - continued**

ENEA

The funds constitute a grant from the European Neuroblastoma Association, a charity based in Italy. The funds were restricted to a specific project, previously agreed with aPODD and a technology collaborator in the UK, Healx Ltd. The funds were to be used by aPODD to fund the project run by Healx aimed at identifying drug repurposing candidates for Neuroblastoma. During the year work was also conducted on this project by the University of Lund, Sweden.

Stripe

These funds came from a crowdfunding campaign raising funds from the general public for a specific research project on paediatric Medulloblastoma. The fundraising project was hosted on the FutSci website (www.futsci.com) and the contributions from the various donors were processed through the online payment platform Stripe (www.stripe.com)

7. **RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 May 2023.